NASDAQ:NVIVInvivo Therapeutics Stock Price, Forecast & News

Invivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVIV stock has decreased by 10.0% and is now trading at $1.44. View which stocks have been most impacted by Coronavirus.

Invivo Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Invivo Therapeutics.

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) released its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter. View Invivo Therapeutics' earnings history.

Invivo Therapeutics's stock reverse split on the morning of Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 11th 2020. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Headlines about NVIV stock have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Invivo Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Invivo Therapeutics.

Invivo Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 202,800 shares, an increase of 36.9% from the June 15th total of 148,100 shares. Based on an average daily trading volume, of 791,700 shares, the short-interest ratio is currently 0.3 days. Approximately 4.5% of the company's stock are short sold. View Invivo Therapeutics' Current Options Chain.

Some companies that are related to Invivo Therapeutics include Neovasc (NVCN), DarioHealth (DRIO), Delcath Systems (DCTH), Biostage (BSTG), Interpace Diagnostics Group (IDXG), Dynatronics (DYNT), Lianluo Smart (LLIT), Avinger (AVGR), Hypertension Diagnostics (HDII), PlusTherapeuticsInc . (PSTV), Hancock Jaffe Laboratories (HJLI), Encision (ECIA), CELLECT BIOTECH/S (APOP), RA Medical Systems (RMED) and Obalon Therapeutics (OBLN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares US Preferred Stock ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), NovaBay Pharmaceuticals (NBY), Apollo Investment (AINV), Inovio Pharmaceuticals (INO), Ophthotech (OPHT) and TrovaGene (TROV).

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVIV stock can currently be purchased for approximately $1.44.

Invivo Therapeutics has a market capitalization of $7.03 million. Invivo Therapeutics employs 6 workers across the globe.

The official website for Invivo Therapeutics is www.invivotherapeutics.com.

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]